Terms: = Head and neck cancer AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4 AND Treatment
1055 results:
1. Genomic Engineering of Oral Keratinocytes to Establish In Vitro Oral Potentially Malignant Disease Models as a Platform for treatment Investigation.
Wils LJ; Buijze M; Stigter-van Walsum M; Brink A; van Kempen BE; Peferoen L; Brouns ER; de Visscher JGAM; van der Meij EH; Bloemena E; Poell JB; Brakenhoff RH
Cells; 2024 Apr; 13(8):. PubMed ID: 38667326
[TBL] [Abstract] [Full Text] [Related]
2. Biplex quantitative PCR to detect transcriptionally active human papillomavirus 16 from patient saliva.
Deutsch F; Sais D; Keatinge N; Hill M; Tran NH; Elliott M; Tran N
BMC Cancer; 2024 Apr; 24(1):442. PubMed ID: 38600473
[TBL] [Abstract] [Full Text] [Related]
3. Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation.
Pershad AR; Thakkar PG; Goodman JF; Joshi A; Steinberg SM; Allen CT; Floudas CS
Cancer Med; 2024 Apr; 13(7):e7146. PubMed ID: 38581118
[TBL] [Abstract] [Full Text] [Related]
4. Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
Meldgaard Justesen M; Kronberg Jakobsen K; Fenger Carlander AL; Hjordt Holm Larsen M; Wessel I; Kiss K; Friborg J; Ibrahim Channir H; Rubek N; Grønhøj C; von Buchwald C
Oral Oncol; 2024 May; 152():106783. PubMed ID: 38569317
[TBL] [Abstract] [Full Text] [Related]
5. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
[TBL] [Abstract] [Full Text] [Related]
6. High p16ink4a Expression, Keratinizing Features, and Surgical Margin-Free Status are Associated with Improved Survival in Patients with Oral Squamous Cell Carcinomas.
Anwar SL; Dwianingsih EK; Lestari SP; Sugandhi W; Cahyono R; Pradana GD
Asian Pac J Cancer Prev; 2024 Mar; 25(3):857-865. PubMed ID: 38546068
[TBL] [Abstract] [Full Text] [Related]
7. Palbociclib inhibits the progression of head and neck cancer and improves the Cetuximab response under specific condition in vitro and in vivo.
Li R; Wang Q; Zhao Y; Zhu Y; Wang X
Mol Biol Rep; 2024 Mar; 51(1):455. PubMed ID: 38536540
[TBL] [Abstract] [Full Text] [Related]
8. Advances in testing for human papillomavirus -mediated head and neck cancer.
Mehanna H; Alemany L; von Buchwald C
Curr Opin Oncol; 2024 May; 36(3):143-146. PubMed ID: 38506408
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation.
Fong PY; Loh TKS; Shen L; Eu DKC; Lim CM
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2645-2653. PubMed ID: 38498191
[TBL] [Abstract] [Full Text] [Related]
10. Effect of radiotherapy on head and neck cancer tissues in patients receiving radiotherapy: a bioinformatics analysis-based study.
Guan Z; Liu J; Zheng L
Sci Rep; 2024 Mar; 14(1):6304. PubMed ID: 38491080
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment.
Payungwong T; Angkulkrerkkrai K; Chaiboonchoe A; Lausoontornsiri W; Jirawatnotai S; Chindavijak S
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2004. PubMed ID: 38477073
[TBL] [Abstract] [Full Text] [Related]
12. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
[TBL] [Abstract] [Full Text] [Related]
13. Clinicopathological and genomic features of superficial esophageal squamous cell carcinomas in nondrinker, nonsmoker females.
Fukuhara M; Urabe Y; Nakahara H; Ishikawa A; Ishibashi K; Konishi H; Mizuno J; Tanaka H; Tsuboi A; Yamashita K; Hiyama Y; Takigawa H; Kotachi T; Yuge R; Hayes CN; Oka S
Cancer Med; 2024 Feb; 13(4):e7078. PubMed ID: 38457229
[TBL] [Abstract] [Full Text] [Related]
14. The mechanisms behind the dual role of long non-coding RNA (lncRNA) metastasis suppressor-1 in human tumors: Shedding light on the molecular mechanisms.
Abdullaev B; Alsaab HO; Hjazi A; Alkhafaji AT; Alawadi AH; Hamzah HF
Pathol Res Pract; 2024 Apr; 256():155189. PubMed ID: 38452581
[TBL] [Abstract] [Full Text] [Related]
15. Detection of antibody subclasses IgA, IgM and IgG against HPV L1 in HPV-positive oropharyngeal squamous cell carcinoma patients: a pilot study.
Weiland T; Zgubic J; Brcic L; Thurnher D
Eur Arch Otorhinolaryngol; 2024 May; 281(5):2637-2644. PubMed ID: 38441604
[TBL] [Abstract] [Full Text] [Related]
16. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis.
Gharzai LA; Morris E; Suresh K; Nguyen-Tân PF; Rosenthal DI; Gillison ML; Harari PM; Garden AS; Koyfman S; Caudell JJ; Jones CU; Mitchell DL; Krempl G; Ridge JA; Gensheimer MF; Bonner JA; Filion E; Dunlap NE; Stokes WA; Le QT; Torres-Saavedra P; Mierzwa M; Schipper MJ
Lancet Oncol; 2024 Mar; 25(3):366-375. PubMed ID: 38423050
[TBL] [Abstract] [Full Text] [Related]
17. Rare case of p16-positive oropharyngeal cancer metastasis to the orbit.
Jeganathan C; Tan JL; Dhepnorrarat C
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38417943
[TBL] [Abstract] [Full Text] [Related]
18. Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma.
Liang S; Ji L; Yu Z; Cheng Y; Gao R; Yan W; Zhang F
Hereditas; 2024 Feb; 161(1):10. PubMed ID: 38414024
[TBL] [Abstract] [Full Text] [Related]
19. Revisiting Feeding Tube Utilization in Oropharynx cancer: 6-Year Prospective Registry Analysis.
Anderson BJ; Moreno AC; Qing Y; Lee JJ; Johnson FM; Lango MN; Barbon CEA; Tripuraneni L; Sahli A; Piper V; Gross N; Fuller CD; Lai SY; Myers JN; Hutcheson KA
Otolaryngol Head Neck Surg; 2024 May; 170(5):1319-1330. PubMed ID: 38353360
[TBL] [Abstract] [Full Text] [Related]
20. Cetuximab treatment beyond Progression in Patients with Recurrent or Metastatic head and neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08).
Wang HM; Lou PJ; Yang MH; Chen TH; Lien MY; Lin JC; Chen JP; Lu WC; Lu HJ; Huang TL; Yen CJ; Wu SY; Wang HC; Hsieh MC
Target Oncol; 2024 Jan; 19(1):51-58. PubMed ID: 38285067
[TBL] [Abstract] [Full Text] [Related]
[Next]
